Characterization, Dynamics, and Mechanism of CXCR4 Antagonists on a Constitutively Active Mutant

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• The G protein-coupled receptor (GPCR) CXCR4 is implicated in HIV, cancers, and autoimmune diseases.
• Targeting CXCR4 dysregulation offers therapeutic potential for various conditions.

Purpose of the Study:

• To characterize novel purine or quinazoline core polyamine pharmacophores as CXCR4 antagonists.
• To elucidate the mechanism of constitutive activation in the N119^3.35A CXCR4 mutant.

Main Methods:

• Pharmacological characterization of five novel CXCR4 ligands.
• Molecular dynamics (MD) simulations and analysis of the IT1t-CXCR4 crystal structure.
• Site-directed mutagenesis of key residues in CXCR4.

Main Results:

• All five compounds acted as neutral antagonists for wild-type CXCR4.
• Two compounds exhibited biased antagonism, affecting β-arrestin-2 at high concentrations.
• The N119^3.35A mutation was hypothesized to increase coupling between transmembrane helices III and VI.
• IT1t was shown to deactivate the constitutively active mutant (CAM) by disrupting TM helix III-VI coupling via residue F87^2.53.
• Mutations at F87^2.53 prevented constitutive signaling and inverse agonism in the N119^3.35A CXCR4 mutant.

Conclusions:

• Characterization of novel CXCR4 ligands with potential therapeutic applications.
• A detailed mechanism for N119^3.35A CXCR4 constitutive activation involving TM helix III-VI coupling was proposed.
• Understanding ligand-mediated disruption of aberrant signaling pathways is crucial for disease intervention.